AOD-9604: What People Actually Pay (Reddit, Clinics, and Compounding Pharmacies)

AOD-9604, also called HGH fragment 176-191, is a synthetic 16-amino-acid peptide modeled on the C-terminal fragment of human growth hormone. It is not an approved drug in the United States. It is not sold under a brand name. Anything a patient buys is either a compounded preparation from a state-licensed 503A pharmacy or an unregulated "research chemical" from an online vendor. That distinction, more than any single dollar figure, is what should drive a purchasing decision.

The evidence-boundary statement

Before any cost discussion, the reader needs to know what AOD-9604's evidence actually shows.

Established: AOD-9604 corresponds to a fragment of the human growth hormone molecule. In an early published study, the fragment reduced fat mass in obese mice over several weeks without the diabetogenic effects associated with full-length growth hormone (Heffernan et al., 2001). AOD-9604 is not FDA-approved, is not indexed as an approved drug product, and is available in the U.S. only through compounding or unregulated peptide vendors.

Plausible but unproven: Some clinicians and manufacturers have proposed that the rodent lipolytic mechanism translates to meaningful human fat loss. This has not been confirmed in a completed, peer-reviewed randomized human trial that we could verify for this article. Reports exist that AOD-9604 reached mid-stage human obesity trials and did not meet its efficacy endpoint, but we could not confirm the primary trial record from the sources available here; this claim should be treated as unconfirmed pending direct verification of the trial registry or publication.

Not established: A specific percentage or pound-based weight-loss effect in humans, a verified safety profile at chronic dosing in people, and any dose-response relationship for fat loss. Reddit and clinic anecdotes describe modest, variable, and confounded outcomes (see below), but self-reports are not a substitute for a controlled trial.

This is the core fact that governs everything about AOD-9604 pricing: AOD-9604 is a compounded, non-FDA-approved peptide whose only substantial supporting evidence is a rodent lipolysis study from 2001; its U.S. price as of 2026 runs from roughly $150 to $450 a month depending on source and formulation, but because no completed human efficacy trial exists, there is no reliable way to calculate a cost-per-outcome figure the way one can for an FDA-approved obesity medication.

Why the price varies so much

AOD-9604 pricing splits into three distinct supply channels, each with a different cost structure:

1. 503A compounding pharmacies fill patient-specific prescriptions under state board oversight and FDA compounding rules. Pricing reflects raw material costs, sterility testing, and beyond-use dating studies (FDA compounding laws and policies).
2. Telehealth peptide clinics bundle a prescriber visit, the compounded product, and sometimes additional peptides into a subscription fee.
3. Gray-market or "research use only" vendors sell peptide vials with no prescriber involvement and no compounding pharmacy oversight. The FDA has published general warnings about unapproved peptide products sold online through its health fraud product database (FDA health fraud database), though that database does not list every vendor or product by name.

What Reddit threads report

Discussions in peptide-focused Reddit communities describe a rough three-tier pattern: people using a U.S. compounding pharmacy with a prescription commonly mention figures in the $200 to $350 per month range; people using a bundled telehealth subscription mention figures from roughly $250 to $449 per month; and people buying research-grade vials from overseas vendors mention per-vial prices as low as $15 to $30, occasionally less with bulk purchases.

These numbers should be read with real caution. The threads are small, self-selected, and skew toward users already comfortable with injectable peptides, often men in their 20s to 40s who have tried other compounds. Individual posts describing an exact monthly price are anecdotal and unverifiable, not a market survey. No structured or peer-reviewed cost survey of AOD-9604 users exists that we could locate.

Compounding pharmacy pricing, itemized

Reported per-unit pricing for compounded injectable AOD-9604, based on publicly listed compounding pharmacy pricing and forum reports:

• 5 mg lyophilized vial: roughly $75 to $150
• Monthly supply at ~300 mcg/day (about 2 vials): roughly $150 to $300
• Monthly supply at ~500 mcg/day (about 3 vials): roughly $225 to $450
• Bacteriostatic water, if not bundled: roughly $8 to $15

Larger vial sizes (10 mg or 15 mg) sometimes lower the per-milligram cost, bringing typical monthly spending down toward $175 to $250. Prices also vary by state, with pharmacies in states that see higher peptide-prescribing volume generally pricing more competitively. These are cost patterns, not a specific pharmacy's rate card, and any given quote should be verified directly with the pharmacy.

Telehealth subscription pricing

Bundled telehealth models typically fall into these publicly advertised tiers:

• Single-peptide plan (AOD-9604 only): roughly $199 to $299/month
• Peptide stack (AOD-9604 with another peptide such as a growth-hormone secretagogue): roughly $349 to $549/month
• Higher-tier plan with labs and recurring provider calls: roughly $449 to $699/month

For a patient who would otherwise pay separately for a consultation and a compounded product, a bundled plan can lower total spending. But bundling also makes it harder to see what portion of the fee covers medical oversight versus product markup. A clinic that folds lab monitoring into the fee, rather than skipping it to keep the headline price low, is doing something clinically meaningful: the Endocrine Society's general position work on hormone-adjacent therapies emphasizes baseline and follow-up monitoring for these categories of treatment (Endocrine Society position statements), even though AOD-9604 itself is not a hormone therapy in the classic sense and is not specifically addressed by name in that guidance.

Gray-market and "research use only" pricing

Unregulated vendors sell AOD-9604 vials labeled for research use only, typically $35 to $80 for a U.S.-based seller and as low as $15 to $30 from some overseas sellers, sometimes less in bulk. These products bypass compounding pharmacy standards entirely: no prescriber, no patient-specific formulation, and no independent verification that the vial contains what the label claims at the stated concentration. Independent testing of gray-market peptides has repeatedly found products with incorrect concentrations or contamination in other peptide categories, though we do not have an AOD-9604-specific testing study to cite here, and that gap should be stated plainly rather than implied.

A patient paying $250 a month through a compounding pharmacy is typically spending several times more than someone buying an unverified vial online. What that higher price buys is documented sterility testing, potency verification, and a legal prescription, not a proven outcome.

AOD-9604 versus GLP-1 medication costs

Patients often compare AOD-9604 to semaglutide or tirzepatide on price alone. That comparison breaks down once the evidence base is considered. In the STEP-1 trial, once-weekly semaglutide 2.4 mg produced substantially greater mean weight loss than placebo over 68 weeks in adults with overweight or obesity (Wilding et al., 2021, NEJM). AOD-9604 has no equivalent completed human trial demonstrating a specific weight-loss effect.

Reported monthly costs, as of 2026:

• Branded semaglutide (Wegovy): list price around $1,349; often $300 to $550 with manufacturer savings programs, subject to change
• Compounded semaglutide: roughly $200 to $500/month, subject to evolving regulatory policy on compounded GLP-1 medications
• Compounded tirzepatide: roughly $250 to $600/month
• Compounded AOD-9604: roughly $150 to $450/month

AOD-9604 can be cheaper at the low end. It is not possible to calculate a cost-per-pound-lost figure for it the way trial data allows for semaglutide, because no rigorous human efficacy trial for AOD-9604 exists in the record available here. Choosing AOD-9604 over a GLP-1 medication on cost grounds means accepting a much weaker evidence base in exchange for a lower price, not finding a cheaper version of the same thing.

What users report about results relative to cost

Forum discussions describe mixed and largely unverifiable outcomes. Recurring themes include:

• Some users describe modest reported fat loss, often in the range of a few pounds over four to eight weeks, almost always while also dieting and exercising, which makes it impossible to isolate the peptide's contribution from self-reports alone.
• A substantial share of posters report no noticeable effect after four to twelve weeks.
• Many users are taking AOD-9604 alongside other peptides or GLP-1 medications simultaneously, which further confounds any attribution of effect to AOD-9604 specifically.

None of this rises to controlled evidence. It describes what people say happened, not what a trial measured.

Hidden costs beyond the vial

The advertised vial or subscription price does not capture full out-of-pocket spending. Patients new to subcutaneous injection typically also need:

• Insulin syringes (29-31 gauge): roughly $15 to $25 per box of 100
• Alcohol swabs: roughly $5 to $10 per box
• Bacteriostatic water, if not included: roughly $8 to $15 per 30 mL vial
• A sharps container: roughly $5 to $10
• An initial provider consultation, if not bundled: roughly $100 to $250
• Follow-up labs, if ordered: roughly $50 to $200 depending on the panel

A first month through a non-subscription compounding pathway, including supplies and an initial visit, can realistically total $350 to $550, settling toward $200 to $350 in subsequent months.

Ways to reduce cost without cutting corners on safety

Requesting a larger vial size (10 mg instead of 5 mg) generally lowers the per-milligram price. Some compounding pharmacies discount 90-day supplies. Injectable formulations avoid paying a premium for oral or sublingual delivery methods whose bioavailability in this context is not established. Getting quotes from more than one compounding pharmacy is worth the effort, since the same vial size can differ meaningfully in price between pharmacies in the same state.

Patients can also confirm a pharmacy's licensing status with their state board of pharmacy before sending payment. Be wary of "free consultation" offers where the consultation cost is likely folded into an inflated product price; pricing that separates the prescriber fee from the product price is easier to evaluate over a multi-month trial.

Baseline fasting glucose, HbA1c, and a lipid panel before starting, repeated at eight to twelve weeks, cost roughly $50 to $150 through direct-to-consumer lab services and are the only objective way to see whether anything measurable is changing, since subjective impressions of fat loss are unreliable over short periods.

A framework for weighing AOD-9604 evidence before you pay

Use this to sort any specific claim about AOD-9604, cost or otherwise, into the right evidence tier before acting on it.

The row that matters most before spending money is the first one: nothing below it changes the fact that human efficacy is not established.

When to involve a clinician rather than a forum

Anyone with diabetes, a history of disordered eating, or a condition requiring metabolic monitoring should talk to a licensed prescriber, not a peptide forum, before starting AOD-9604 or any compounded peptide. Unexplained injection-site reactions, signs of infection, or new symptoms after starting an unregulated peptide warrant urgent medical evaluation rather than a wait-and-see approach on Reddit.